Satoru Tada

Dr. Satoru Tada

Osaka University, Ōsaka, Japan
+2
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KSKurt A. Sailor
Kurt A. Sailor
GAGeorge Agoranos
George Agoranos
SLSergio López-Manzaneda
Sergio López-Manzaneda
STSatoru Tada
Satoru Tada
BGBeatrix Gillet-Legrand
Beatrix Gillet-Legrand
NCNathalie Cartier
Nathalie Cartier
Hematopoietic stem cell transplantation (HSCT) is a therapy used for multiple malignant and nonmalignant diseases, with chemotherapy used for pretransplantation myeloablation. The post-HSCT brain contains peripheral engrafted parenchymal macrophages, despite their absence in the normal brain, with the engraftment mechanism still undefined. Here we show that HSCT chemotherapy broadly disrupts mouse brain regenerative populations, including a permanent loss of adult neurogenesis. Microglial density was halved, causing microglial process expansion, coinciding with indicators of broad senescence. Although microglia expressed cell proliferation markers, they underwent cell cycle arrest in S phase with a majority expressing the senescence and antiapoptotic marker p21. In vivo single-cell tracking of microglia after recovery from chemical depletion showed loss of their regenerative capacity, subsequently replaced with donor macrophages. We propose that HSCT chemotherapy causes microglial senescence with a gradual decrease to a critical microglial density, providing a permissive niche for peripheral macrophage engraftment of the brain.

18 March 2019 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
BSBenoît Souchet
Benoît Souchet
MAMickael Audrain
Mickael Audrain
JBJean Marie Billard
Jean Marie Billard
JDJulien Dairou
Julien Dairou
RFRomain Fol
Romain Fol
NCNathalie Cartier
Nathalie Cartier
Recent evidences suggest the involvement of DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1 A) in Alzheimer’s disease (AD). Here we showed that DYRK1A undergoes a proteolytic processing in AD patients hippocampus without consequences on its kinase activity. Resulting truncated forms accumulate in astrocytes and exhibit increased affinity towards STAT3ɑ, a regulator of inflammatory process. These findings were confirmed in APP/PS1 mice, an amyloid model of AD, suggesting that this DYRK1A cleavage is a consequence of the amyloid pathology. We identified in vitro the Leucettine L41 as a compound able to prevent DYRK1A proteolysis in both human and mouse protein extracts. We then showed that intraperitoneal injections of L41 in aged APP/PS1 mice inhibit STAT3ɑ phosphorylation and reduce pro-inflammatory cytokines levels (IL1- β, TNF-ɑ and IL-12) associated to an increased microglial recruitment around amyloid plaques and decreased amyloid-β plaque burden. Importantly, L41 treatment improved synaptic plasticity and rescued memory functions in APP/PS1 mice. Collectively, our results suggest that DYRK1A may contribute to AD pathology through its proteolytic process, reducing its kinase specificity. Further evaluation of inhibitors of DYRK1A truncation promises a new therapeutic approach for AD.

1 September 2018 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
ASAri Shinojima
Ari Shinojima
IKItsuhiro Kakeya
Itsuhiro Kakeya
STSatoru Tada
Satoru Tada
Space flight–associated neuroocular syndrome (SANS), characterized by increased optic nerve sheath diameter (ONSD) and globe flattening, is detected in some astronauts.1 Because inflight cerebrospinal fluid (CSF) pressure measurement is excessively invasive, it is not realistic to conduct. We estimated CSF pressure (pCSF) during space flight based on published reports2 and found that SANS was not caused mainly by increased pCSF but rather by brain upward shift (BUS), recently demonstrated in postflight astronauts.3 Our findings suggest that eyes are portals into effects on the brain during space flight.

1 September 2019 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
NONicola Orefice
Nicola Orefice
BSBenoît Souchet
Benoît Souchet
Jérôme BraudeauJérôme Braudeau
Jérôme Braudeau
SASandro Alves
Sandro Alves
FPFrançoise Piguet
Françoise Piguet
NCNathalie Cartier
Nathalie Cartier
Exosomes represent a strategy for optimizing the adeno-associated virus (AAV) toward the development of novel therapeutic options for neurodegenerative disorders. However, in vivo spreading of exosomes and AAVs after intracerebral administration is poorly understood. This study provides an assessment and comparison of the spreading into the brain of exosome-enveloped AAVs (exo-AAVs) or unassociated AAVs (std-AAVs) through in vivo optical imaging techniques like probe-based confocal laser endomicroscopy (pCLE) and ex vivo fluorescence microscopy. The std-AAV serotypes (AAV6 and AAV9) encoding the GFP were enveloped in exosomes and injected into the ipsilateral hippocampus. At 3 months post-injection, pCLE detected enhanced GFP expression of both exo-AAV serotypes in contralateral hemispheres compared to std-AAVs. Although sparse GFP-positive astrocytes were observed using exo-AAVs, our results show that the enhancement of the transgene expression resulting from exo-AAVs was largely restricted to neurons and oligodendrocytes. Our results suggest (1) the possibility of combining gene therapy with an endoscopic approach to enable tracking of exo-AAV spread, and (2) exo-AAVs allow for widespread, long-term gene expression in the CNS, supporting the use of exo-AAVs as an efficient gene delivery tool.

8 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJosephe Archie Honorat
Josephe Archie Honorat
MKMakoto Kinoshita
Makoto Kinoshita
TOTatsusada Okuno
Tatsusada Okuno
KTKazushiro Takata
Kazushiro Takata
TKToru Koda
Toru Koda
YNYuji Nakatsuji
Yuji Nakatsuji
Oxidative stress plays an important role in the pathogenesis of multiple sclerosis (MS). Though reactive oxygen species (ROS) are produced by various mechanisms, xanthine oxidase (XO) is a major enzyme generating ROS in the context of inflammation. The objectives of this study were to investigate the involvement of XO in the pathogenesis of MS and to develop a potent new therapy for MS based on the inhibition of ROS. XO were assessed in a model of MS: experimental autoimmune encephalomyelitis (EAE). The contribution of XO-generated ROS to the pathogenesis of EAE was assessed by treating EAE mice with a novel XO inhibitor, febuxostat. The efficacy of febuxostat was also examined in in vitro studies. We showed for the first time that the expression and the activity of XO were increased dramatically within the central nervous system of EAE mice as compared to naïve mice. Furthermore, prophylactic administration of febuxostat, a XO inhibitor, markedly reduced the clinical signs of EAE. Both in vivo and in vitro studies showed infiltrating macrophages and microglia as the major sources of excess XO production, and febuxostat significantly suppressed ROS generation from these cells. Inflammatory cellular infiltration and glial activation in the spinal cord of EAE mice were inhibited by the treatment with febuxostat. Importantly, therapeutic efficacy was observed not only in mice with relapsing-remitting EAE but also in mice with secondary progressive EAE by preventing axonal loss and demyelination. These results highlight the implication of XO in EAE pathogenesis and suggest XO as a target for MS treatment and febuxostat as a promising therapeutic option for MS neuropathology.

23 February 2011 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
STSatoru Tada
Satoru Tada
TOTatsusada Okuno
Tatsusada Okuno
TYTeruhito Yasui
Teruhito Yasui
YNYuji Nakatsuji
Yuji Nakatsuji
TSTomoyuki Sugimoto
Tomoyuki Sugimoto
SSSaburo Sakoda
Saburo Sakoda
Non-neuronal cells, such as microglia and lymphocytes, are thought to be involved in the pathogenesis of amyotrophic lateral sclerosis (ALS). Previous studies have demonstrated neuroprotective effects of lymphocytes at the end stage of ALS, partly through induction of alternatively activated microglia (M2 microglia), which are neuroprotective. In this study, we investigated the role of lymphocytes in the early stage of the disease using an animal model of inherited ALS.